Roche RHHBY announced that the late-stage study, PEMPHIX, on its rheumatoid arthritis (RA) drug, MabThera/Rituxan for the indication of pemphigus vulgaris (PV) was successful. We note that Rituxan ...

The latest comes from a promising study that found Rituxan cut the risk of relapse in Multiple Sclerosis patients in half. Rituxan, sold by Genentech and Biogen Idec, targets immune system cells ...

This can be attributed to expected competition for Rituxan from biosimilars, given its market exclusivity period ended last year, and it is expected to see a decline in sales. Chronic lymphocytic ...

Health Canadahas revised prescribing information for the medication Rituxan after some people taking the drugfor non-Hodgkin's lymphoma developed potentially life-threatening bowel obstruction or ...

DailyUpdates March 1 st, 2006: Genentech and Biogen Idec announced yesterday (press release) that the FDA has approved Rituxan (Rituximab) in combination with methotrexate to reduce signs and symptoms ...

The disease can be life threatening. Phase 3 study results released last March demonstrated Rituxan substantialy improved pemphigus vulgaris remission rates and successful tapering. The Food and ...

ABBVIE - IN STUDY, ADVERSE EVENTS WERE CONSISTENT WITH KNOWN SAFETY PROFILE OF VENCLEXTA/VENCLYXTO AND RITUXAN * ABBVIE - GRADE 3-4 NEUTROPENIA WAS HIGHER IN VENCLEXTA/VENCLYXTO IN COMBINATION ...

In an interview with CURE®, a Waldenstrom’s macroglobulinemia expert discusses the long-term benefits of the targeted combination of Imbruvica and Rituxan. Data from a five-year analysis demonstrate ...

CHICAGO--In February, Roche ($RHHBY) said its Rituxan follow-up, Gazyva, had succeeded in a late-stage study involving non-Hodgkin lymphoma (NHL) patients, extending ...